[HTML][HTML] Defining the risk of SARS-CoV-2 variants on immune protection

MM DeGrace, E Ghedin, MB Frieman, F Krammer… - Nature, 2022 - nature.com
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …

[HTML][HTML] Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity

HM Mengist, AJK Kombe, D Mekonnen, A Abebaw… - Seminars in …, 2021 - Elsevier
Responsible for more than 4.9 million deaths so far, COVID-19, caused by SARS-CoV-2, is
instigating devastating effects on the global health care system whose impacts could be …

SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

S Lusvarghi, SD Pollett, SN Neerukonda… - Science Translational …, 2022 - science.org
The rapid spread of the highly contagious Omicron variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) along with its high number of mutations in the spike …

[HTML][HTML] The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

S Rothenberger, DL Hurdiss, M Walser… - Nature …, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with potential resistance to existing drugs emphasizes the need for new therapeutic …

SARS-CoV-2 BA. 2.86 enters lung cells and evades neutralizing antibodies with high efficiency

L Zhang, A Kempf, I Nehlmeier, A Cossmann, A Richter… - Cell, 2024 - cell.com
Summary BA. 2.86, a recently identified descendant of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) Omicron BA. 2 sublineage, contains∼ 35 mutations …

[HTML][HTML] SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

S Lusvarghi, SD Pollett, SN Neerukonda, W Wang… - BioRxiv, 2021 - ncbi.nlm.nih.gov
The rapid spread of the highly contagious Omicron variant of SARS-CoV-2 along with its
high number of mutations in the spike gene has raised alarm about the effectiveness of …

[HTML][HTML] Multiplex PCR assays for identifying all major severe acute respiratory syndrome coronavirus 2 variants

RJ Dikdan, SAE Marras, AP Field, A Brownlee… - The Journal of molecular …, 2022 - Elsevier
Variants of concern (VOC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), including alpha, beta, gamma, delta, and omicron, threaten to prolong the pandemic …

[HTML][HTML] Cross-reactivity assessment of vaccine-derived SARS-CoV-2 T cell responses against BA. 2.86 and JN. 1

MS Sohail, SF Ahmed, AA Quadeer, MR McKay - Viruses, 2024 - mdpi.com
The SARS-CoV-2 Omicron sub-variants BA. 2.86 and JN. 1 contain multiple mutations in the
spike protein that were not present in previous variants of concern and Omicron sub …

The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics

F Eilts, S Bauer, K Fraser, JS Dordick, MW Wolff… - Carbohydrate …, 2023 - Elsevier
In December 2019, the global coronavirus disease 2019 (COVID-19) pandemic began in
Wuhan, China. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 …

[HTML][HTML] SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced …

SN Neerukonda, R Vassell, S Lusvarghi, R Wang… - Viruses, 2021 - mdpi.com
The SARS-CoV-2 B. 1.617 lineage variants, Kappa (B. 1.617. 1) and Delta (B. 1.617. 2, AY)
emerged during the second wave of infections in India, but the Delta variants have become …